Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Feb;47(1):157-165.
doi: 10.1007/s11096-024-01819-6. Epub 2024 Oct 28.

Credentialed pharmacist-led home medicines reviews targeting treatable traits and their impact on health outcomes in people with chronic obstructive pulmonary disease: a pre- and post-intervention study

Muhammad Rehan Sarwar  1 , Vanessa Marie McDonald  2   3   4 , Michael J Abramson  5 , Sally Wilson  1 , Anne E Holland  6 , Billie Bonevski  7 , Ajay Mahal  8 , Eldho Paul  5 , Brian Meier  1 , Johnson George  9
Affiliations
Randomized Controlled Trial

Credentialed pharmacist-led home medicines reviews targeting treatable traits and their impact on health outcomes in people with chronic obstructive pulmonary disease: a pre- and post-intervention study

Muhammad Rehan Sarwar et al. Int J Clin Pharm. 2025 Feb.

Erratum in

Abstract

Background: Patients with chronic obstructive pulmonary disease (COPD) should engage in self-management strategies targeting behavioural traits and lifestyle risk-factors for optimal outcomes.

Aim: To evaluate the impact of credentialed pharmacist-led home medicines review (HMR) targeting treatable traits (TTs) on health outcomes in COPD in primary care.

Method: A pre- and post-intervention study was nested within a cluster-randomised controlled trial. A total of 81 participants with COPD from 21 Australian general practices received an HMR with a credentialed pharmacist targeting TTs. Changes in health outcomes at 6 and 12 months from baseline were assessed.

Results: Ten TTs were assessed and targeted during the HMR. At baseline, no-one had a written action plan for managing exacerbations, and medication adherence was sub-optimal in 85% of patients. Additionally, 53% of participants demonstrated inadequate inhaler device technique, while 52% were current smokers. At 6-months follow-up, significant improvements were observed in health-related quality of life (St. George's Respiratory Questionnaire score = 34.6 versus 39.1 at baseline, p = 0.006), health status (COPD Assessment Test score = 12 versus 16, p = 0.002), anxiety (Hospital Anxiety and Depression Scale (HADS)-Anxiety score = 2.0 versus 5.0, p < 0.001), depression (HADS-Depression score = 1.0 versus 5.0, p < 0.001), self-reported smoking (47% versus 51.9%, p = 0.031) and treatment adherence (Tool for Adherence Behaviour Screening score = 12.5 versus 10.0, p = 0.002). At 12-months: health status, anxiety, depression, smoking abstinence and adherence to treatment, continued to show statistically significant improvements compared to baseline measurements.

Conclusion: HMRs targeting TTs improved health outcomes in people with COPD. Credentialed pharmacists in primary care can work alongside general practitioners to optimise COPD management.

Keywords: Chronic obstructive pulmonary disease; Home medicines review; Medication adherence; Pharmacists; Treatable traits.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interests: MJA holds investigator-initiated grants for unrelated research from Pfizer, Boehringer Ingelheim, Sanofi and GSK. He has also undertaken an unrelated consultancy (paid to his employer) for Sanofi and received a speaker’s fee from GSK. VM has received research funding from AstraZeneca, Cyclopharm, GSK, NHMRC, and Ramaciotti; speaker’s honoraria from AstraZeneca, Boehringer Ingelhiem, and GSK; and provided consultancy for AstraZeneca, GSK, and Menarini. JG holds investigator-initiated grants for unrelated research from Pfizer, GSK and Boehringer Ingelheim. He has received honoraria (paid to his employer) from a consultancy for GSK, AstraZeneca and for invited presentations at a continuing education event organised by Pfizer. The other authors declare no conflicts of interest.

References

    1. World Health Organization. The top 10 causes of death. 2020; Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed 10 March 2024.
    1. Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23. - PubMed
    1. Boers E, Barrett M, Su JG, et al. Global burden of chronic obstructive pulmonary disease through 2050. JAMA Netw Open. 2023;6(12):e2346598–e2346598. - PMC - PubMed
    1. George J, Kong DC, Thoman R, et al. Factors associated with medication nonadherence in patients with COPD. Chest. 2005;128(5):3198–204. - PubMed
    1. Jarab AS, Alqudah SG, Khdour M, et al. Impact of pharmaceutical care on health outcomes in patients with COPD. Int J Clin Pharm. 2012;34(1):53–62. - PubMed

Publication types

LinkOut - more resources